



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Refine Search

Search Results -

Term	Documents
LEUPOLIDE	0
LEUPOLIDES	0
((LEUPOLIDE OR 4) AND 11).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	24
(L11 AND (L4 OR LEUPOLIDE)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	24

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L12

Search History

DATE: Wednesday, December 26, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;</i>			
<i>OP=AND</i>			
<u>L12</u>	L11 and (L4 or leupolide)	24	<u>L12</u>
<u>L11</u>	L5 and (IL-7 or (growth adj hormone))	581	<u>L11</u>
<u>L10</u>	L9 and (leuprolide)	15	<u>L10</u>
<u>L9</u>	L8 and (hematopoietic adj stem)	33	<u>L9</u>
<u>L8</u>	L7 and L5	60	<u>L8</u>
<u>L7</u>	(T adj cell) same (depleting or ablating)	897	<u>L7</u>
<u>L6</u>	L5 and L4	27	<u>L6</u>

<u>L5</u>	L2 and ((autoimmune adj disease) or diabetes)	1176	<u>L5</u>
<u>L4</u>	(sex adj steroid) same (inhibition or disruption or blockage or disrupting)	265	<u>L4</u>
<u>L3</u>	L2 and ((autoimmune adj disease) or diabetes)	898	<u>L3</u>
<u>L2</u>	(thymus or thymic) same (stimulation or regeneration or activating or reactivating)	1959	<u>L2</u>
<u>L1</u>	Boyd-Richard-L\$.in.	15	<u>L1</u>

END OF SEARCH HISTORY

Welcome to DialogClassic Web(tm)

Dialog level 05.20.01D

Last logoff: 13dec07 17:06:13

Logon file1 26dec07 14:06:44

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

***BIOSIS Previews Archive (File 552)

***BIOSIS Previews 1969-2007 (File 525)

***Trademarkscan - South Korea (File 655)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

***Files 72 & 73, EMBASE

***Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online

NEWS

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

>>>For the latest news about Dialog products, services, content<<< >>>and events, >>><http://www.dialog.com/whatsnew/>. You can find news about<<< >>>a specific database by entering HELP NEWS <file number>.<<< >>>PROFILE is in a suspended state. >>>Contact Dialog Customer Services to re-activate it.

* * *

File 1:ERIC 1965-2007/Nov

(c) format only 2007 Dialog

Set Items Description

--- -----

Cost is in DialUnits

?

B 155, 159, 5, 73

26dec07 14:06:58 User259876 Session D1058.1

\$0.98 0.279 DialUnits File1

\$0.98 Estimated cost File1

\$0.05 INTERNET

\$1.03 Estimated cost this search

\$1.03 Estimated total session cost 0.279 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2007/Nov 30

(c) format only 2007 Dialog

*File 155: MEDLINE has ceased updating with UD20071203. Please see HELP NEWS 154 for details.

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

*File 159: Cancerlit is no longer updating. Please see HELP NEWS159.

File 5:Biosis Previews(R) 1926-2007/Dec W3

(c) 2007 The Thomson Corporation

File 73:EMBASE 1974-2007/Dec 20

(c) 2007 Elsevier B.V.

*File 73: The file has been reloaded and accession numbers have changed. See HELP NEWS 72 for details.

Set	Items	Description
---	-----	-----

?

S (THYMUS OR THYMIC) (S) (STIMULATION OR REGENERATION OR ACTIVATING OR REACTIVATING
 197352 THYMUS
 58585 THYMIC
 1358666 STIMULATION
 221326 REGENERATION
 227197 ACTIVATING
 0 REACTIVATING
 S1 11985 (THYMUS OR THYMIC) (S) (STIMULATION OR REGENERATION OR
 ACTIVATING OR REACTIVATING)

?

S1 AND ((AUTOIMMUNE (W) DISEASE) OR DIABETES)

Processing

Processing

12084193	1	
235396		AUTOIMMUNE
8252380		DISEASE
67459		AUTOIMMUNE(W)DISEASE
743813		DIABETES
S2 302921	1	AND ((AUTOIMMUNE (W) DISEASE) OR DIABETES)

?

S S2 AND (LUPROLIDE)

302921	S2	
38		LUPROLIDE
S3 0		S2 AND (LUPROLIDE)

?

Set	Items	Description
S1	11985	(THYMUS OR THYMIC) (S) (STIMULATION OR REGENERATION OR ACT-

		IVATING OR REACTIVATING)
--	--	--------------------------

S2	302921	1 AND ((AUTOIMMUNE (W) DISEASE) OR DIABETES)
----	--------	--

S3	0	S2 AND (LUPROLIDE)
----	---	--------------------

?

S S2 AND (IL-7 OR (GROWTH (W) HORMONE))

302921	S2	
44		IL-7
3076823		GROWTH
1227912		HORMONE
178722		GROWTH(W)HORMONE
S4 4572		S2 AND (IL-7 OR (GROWTH (W) HORMONE))

?

S S4 AND ((BONE (W) MARROW) OR HSC OR (HEMATOPOIETIC (W) STEM))

4572	S4	
1518872		BONE
587876		MARROW
556291		BONE(W)MARROW
11442		HSC
206560		HEMATOPOIETIC

551584 STEM
 110649 HEMATOPOIETIC(W)STEM
 S5 18 S4 AND ((BONE (W) MARROW) OR HSC OR (HEMATOPOIETIC (W)
 STEM))

?

RD

S6 16 RD (unique items)

?

T S6/3,K/ALL

6/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

14953169 PMID: 15205084

Growth and endocrine function following bone marrow transplantation for thalassemia major.

Li Chi Kong; Chik Ki Wai; Wong Gary Wing Kin; Cheng Pik Shun; Lee Vincent; Shing Matthew Ming Kong

Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, China. ckli@cuhk.edu.hk

Pediatric hematology and oncology (England) Jul-Aug 2004, 21 (5)

p411-9, ISSN 0888-0018--Print Journal Code: 8700164

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Growth and endocrine function following bone marrow transplantation for thalassemia major.

... and endocrine dysfunction. Thirty-two TM patients who had survived more than 2 years after bone marrow transplantation (BMT) were recruited for growth and endocrine study. Patients were followed up annually for...

...the height was expressed as height standard deviation score (HtSDS). The HtSDS at baseline was - 1 .51 and was more reduced in patients older than 7 years (- 1 .99) as compared with those younger patients (-0.79) (p =.027). The HtSDS gradually improved after BMT and increased by 0.59 (CI 0.16- 1 .01) at 5 years after BMT. Forty percent of patients were below 2 SD at...

... 10 boys had spontaneous puberty but 3 of them had gonadal impairment. One patient developed diabetes mellitus and one had growth hormone deficiency after BMT. In conclusion, improvement of growth after BMT in TM was common. Gonadal...

Descriptors: *Bone Marrow Transplantation; *Child Development--physiology--PH; *Endocrine System--physiology--PH; *Growth Disorders--etiology--ET; *beta-Thalassemia...

; Adolescent; Bone Marrow Transplantation--adverse effects--AE; Child; Endocrine System--physiopathology--PP; Follow-Up Studies; Graft vs Host...

6/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

14017451 PMID: 12430895

Chronic graft-versus-host disease and late effects after hematopoietic

stem cell transplantation.

Sanders Jean E

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

International journal of hematology (Ireland) Aug 2002, 76 Suppl 2
p15-28, ISSN 0925-5710--Print Journal Code: 9111627

Contract/Grant No.: CA18029; CA; NCI; HL3644; HL; NHLBI

Publishing Model Print

Document type: Journal Article; Research Support, U.S. Gov't, P.H.S.;
Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation.

... system, eyes, lungs, bone, and development of secondary malignancies. Endocrine deficiencies include growth failure with growth hormone (GH) deficiency, overt hypothyroidism, primary gonadal failure, Type 1 or Type 2 diabetes, and exocrine pancreatic insufficiency. These problems develop at any time post-HSCT, but usually occur...

Descriptors: *Graft vs Host Disease; * Hematopoietic Stem Cell Transplantation--adverse effects--AE

6/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

13444391 PMID: 11678978

Adverse metabolic and cardiovascular risk following treatment of acute lymphoblastic leukaemia in childhood; two case reports and a literature review.

Amin P; Shah S; Walker D; Page S R

Department of Diabetes, Endocrinology and Clinical Nutrition, University Hospital NHS Trust, Queen's Medical Centre, Nottingham, UK.

Diabetic medicine - a journal of the British Diabetic Association (England) Oct 2001, 18 (10) p849-53, ISSN 0742-3071--Print

Journal Code: 8500858

Publishing Model Print

Document type: Case Reports; Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... survived childhood acute lymphoblastic leukaemia (ALL) following treatment with chemotherapy, total body irradiation (TBI) and bone marrow transplantation (BMT). The first case presented with an acute cerebral infarction at 23 years of age and was found to have non-ketotic diabetes and gross mixed hyperlipidaemia; the second presented with non-ketotic diabetes, hypertension, proteinuria and dyslipidaemia at age 16 years. The association of glucose intolerance with other...

... of BMT was recently highlighted in a follow-up study of 23 survivors of BMT [1], but none presented with such gross mixed hyperlipidaemia. The improving survival rates of childhood malignancy...

; Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; England; European Continental Ancestry Group; Glucose Intolerance --etiology--ET; Human Growth Hormone --deficiency--DF; Human Growth Hormone --therapeutic use--TU; Humans; Leukemia, Lymphocytic, Acute, L1 --therapy--TH; Ovarian Cysts--etiology--ET; Ovarian...

Chemical Name: Human Growth Hormone

6/3,K/4 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

0019586734 BIOSIS NO.: 200700246475

Single centre evaluation of endocrine complications in children treated with auto- and allo-haematopoietic stem cell transplantation (HSCT).

AUTHOR: Wojcik Dorota M (Reprint); Niedzielska Ewa; Barg Ewa; Kalwak Krzysztof; Gorczynska Ewa; Doroszko Adrian; Chybicka Alicja

AUTHOR ADDRESS: Med Univ, Dept Children Bone Marrow Transplantat Oncol Hema, Wroclaw, Poland**Poland

JOURNAL: Blood 108 (11, Part 2): p425B NOV 16 2006 2006

CONFERENCE/MEETING: Symposium of the

International-Society-of-Molecular-Evolution GUANANACASTE, COSTA RICA

January 08 -12, 2001; 20010108

SPONSOR: Int Soc Molec Evolut

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: each patient. The University Research Committee for Bioethics did consent to this investigation protocol. Results 1 . 16 children (11girls and 5 boys) presented with abnormal puberty: 43,75% after auto-and...

...70 months after allo- transplantation (average 36 months). Three children from above group received CL Growth hormone substitution was instituted in 1 . girl (ALL, HLA MM REL, CI). (SDS <-2,0). 5. An impaired glucose-curve with...

...was found in 7 patients: 4 treated with auto- and 3 with allo-HSCT. No diabetes mellitus occurred so far. Conclusions 1 .Early endocrinological care of children treated with both auto-, as well as allo-HSCT is...

DESCRIPTORS:

...METHODS & EQUIPMENT: allo- hematopoietic stem cell transplantation ...

...auto- hematopoietic stem cell transplantation...

6/3,K/5 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18838032 BIOSIS NO.: 200600183427

NCI Fanconi's anemia cohort: Hematology and beyond.

AUTHOR: Giri Neelam (Reprint); Batista Dalia; Stratakis Constantine; Tsilou Ekaterini T; Kim Hung J; Alter Blanche P

AUTHOR ADDRESS: NCI, Clin Genet Branch, DCEG, Bethesda, MD 20892 USA**USA

JOURNAL: Blood 106 (11, Part 1): p308A NOV 16 2005 2005

CONFERENCE/MEETING: 47th Annual Meeting of the

American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005; 20051210

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: had at least one FA-related congenital anomaly. 11 patients were FANCA, 9 FANCC, and 1 each FANCD1/BRCA2, FANCF, and FANCI. 34/42 (81%) had aplastic anemia; 10 had mild to moderate and 24 had severe AA. 13/33 (38 %) had clonal cytogenetic bone marrow abnormalities, some for > 3 years. 8/42 (19%) developed MDS, one of whom evolved to...
...hypopigmented areas, and 2 had Sweet's syndrome with MDS. 9/19 (47%) had leukoplakia; 1 biopsy was positive for SCC. 29/42 (69%) had one or more endocrinopathy, including short stature, hypothyroidism, growth hormone deficiency, glucose intolerance, diabetes, dyslipidemia and metabolic syndrome. 5 patients had midline structural anomalies of the brain, and 1 each had a lipoma and a brain tumor. 2 patients had nonalcoholic steatohepatitis, 1 had transfusional hemosiderosis and 1 had a liver adenoma. 7/8 adult females had infertility and premature ovarian failure; 5...

...age of 29 yrs (range 5-44), including 5 head and neck, 4 vulvar, and 1 each nasopharyngeal, skin and brain tumor. One of the head and neck SCC occurred 13...

DESCRIPTORS:

ORGANISMS: PARTS ETC: bone marrow --

...METHODS & EQUIPMENT: bone marrow transplantation

6/3,K/6 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18833290 BIOSIS NO.: 200600178685

7th Annual Meeting of the

European-Society-of-Veterinary-Clinical-Pathology, Utrecht, NETHERLANDS,

June 21 -24, 2005

AUTHOR: Anonymous

JOURNAL: Veterinary Clinical Pathology 34 (Suppl. S): p292-314 2005 2005

CONFERENCE/MEETING: 7th Annual Meeting of the

European-Society-of-Veterinary-Clinical-Pathology Utrecht, NETHERLANDS

June 21 -24, 2005; 20050621

SPONSOR: European Soc Vet Clin Pathol

ISSN: 0275-6382

DOCUMENT TYPE: Meeting

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: hyperfibrinogenolysis in dogs, biochemical markers of bone metabolism in cows, mast cell hyperplasia in the bone marrow of dogs, oxidative stress markers during lactation in dairy cows, monitoring cattle that survived accidental...

...REGISTRY NUMBERS: growth hormone ;

DESCRIPTORS:

DISEASES: diabetes mellitus...

MESH TERMS: Diabetes Mellitus (MeSH...

CHEMICALS & BIOCHEMICALS: ... growth hormone ; ...

...alpha- 1 acid glycoprotein

6/3,K/7 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0081595500 EMBASE No: 2007028792

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: A double-blind randomized, placebo-controlled study

Sirohi B.; Powles R.; Morgan G.; Treleaven J.; Kulkarni S.; Horton C.; Saso R.; Rolfe D.; Cook G.; Shaw C. // Wass J.

Haemato-Oncology Unit, Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, United Kingdom // Department of Endocrinology, Churchill Hospital, Oxford, United Kingdom

CORRESP. AUTHOR: Powles R.

CORRESP. AUTHOR AFFIL: Haemato-Oncology Unit, Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, United Kingdom

Bone Marrow Transplantation (Bone Marrow Transplant.) (United Kingdom)
January 1, 2007, 39/2 (115-120)

CODEN: BMTRE ISSN: 02683369 eISSN: 14765365

PUBLISHER ITEM IDENTIFIER: 1705545

DOI: 10.1038/sj.bmt.1705545

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 27

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: A double-blind randomized, placebo-controlled...

In vivo and in vitro studies suggest human growth hormone (hGH) receptors on bone marrow stem cells may be biologically active and could be exploited to promote haemopoetic recovery after...

...16 versus 19 days; P=0.03) compared to the placebo-controlled arm (hazard ratio 1.47 favouring hGH, 95% confidence interval (CI), 1.03-2.08). Time to relapse did not differ significantly between arms. There was no...

DRUG DESCRIPTORS:

*antineoplastic agent--drug therapy--dt; *human growth hormone --adverse drug reaction--ae; *human growth hormone --clinical trial--ct; *human growth hormone --drug therapy--dt; *human growth hormone --intravenous drug administration--iv; *human growth hormone --subcutaneous drug administration--sc

MEDICAL DESCRIPTORS:

...combination chemotherapy; cancer relapse; clinical trial; confidence interval; controlled clinical trial; controlled study; crossover procedure; diabetes mellitus--drug therapy--dt; double blind procedure; drug safety; drug tolerability; female; hospitalization; human; major...

...CAS REGISTRY NO.: 25316-40-9 (doxorubicin); 33419-42-0 (etoposide); 12629-01-5 (human growth hormone); 9004-10-8 (insulin); 15475-56-6

...

6/3,K/8 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0081214144 EMBASE No: 2006276775

Perioperative acute renal failure

Mahon P.; Shorten G.

Department of Anaesthesia, Cork University Hospital, Wilton, Cork, Ireland

AUTHOR EMAIL: rsimahon@hotmail.com
CORRESP. AUTHOR: Mahon P.
CORRESP. AUTHOR AFFIL: Department of Anaesthesia, Cork University
Hospital, Wilton, Cork, Ireland
CORRESP. AUTHOR EMAIL: rsimahon@hotmail.com

Current Opinion in Anaesthesiology (Curr. Opin. Anaesthesiol.) (United
Kingdom) June 1, 2006, 19/3 (332-338)
CODEN: COAEE ISSN: 09527907
DOI: 10.1097/01.aco.0000192819.76353.b3
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 73

...postoperative acute renal failure. In the future, strategies targeting
renal regeneration after injury will use bone marrow -derived stem cells
and growth factors such as insulin-like growth factor- 1 . (c) 2006
Lippincott Williams & Wilkins.

DRUG DESCRIPTORS:

...drug therapy--dt; fenoldopam mesilate--pharmacology--pd; furosemide
--drug therapy--dt; furosemide--pharmacology--pd; human growth hormone
--drug therapy--dt; human growth hormone --pharmaceutics--pr; human
growth hormone --pharmacology--pd; nucleotide--pharmaceutics--pr;
nucleotide--pharmacology--pd; oligonucleotide--pharmaceutics--pr;
oligonucleotide--pharmacology--pd; parvovirus...

MEDICAL DESCRIPTORS:

anesthesiological techniques; clinical trial; creatinine blood level; crush
trauma; diabetes mellitus; disease association; disease predisposition;
edema; electroporation; endothelium cell; epidemiological data;
experimental rat; gene therapy...

...CAS REGISTRY NO.: 7 (dopamine); 67227-57-0 (fenoldopam mesilate);
54-31-9 (furosemide); 12629-01-5 (human growth hormone); 68562-41-4
(recombinant somatomedin C)

6/3,K/9 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0079693810 EMBASE No: 2003403006

American Society of Gene Therapy - Fifth Annual Meeting: 4-9 June 2002,
Boston, MA, USA

Finn J.D.

University of British Columbia, Dept. of Biochem. Molec. Biol., 2146
Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada

AUTHOR EMAIL: jdfinn@interchange.ubc.ca

CORRESP. AUTHOR: Finn J.D.

CORRESP. AUTHOR AFFIL: University of British Columbia, Dept. of Biochem.
Molec. Biol., 2146 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada

CORRESP. AUTHOR EMAIL: jdfinn@interchange.ubc.ca

IDrugs (IDrugs) (United Kingdom) December 1, 2002, 5/7 (670-674)

CODEN: IDRUF ISSN: 13697056

DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

DRUG DESCRIPTORS:

...stimulating factor--pharmacology--pd; green fluorescent protein--drug
therapy--dt; green fluorescent protein--pharmacology--pd; growth hormone
releasing factor--drug combination--cb; growth hormone releasing

factor--pharmaceutics--pr; growth hormone releasing factor
 --pharmacology--pd; hoe 33342--drug combination--cb; hoe 33342
 --pharmaceutics--pr; hoe 33342...

MEDICAL DESCRIPTORS:

...immunodeficiency--drug therapy--dt; combined immunodeficiency--therapy
 --th; conference paper; cystic fibrosis--drug therapy--dt; diabetes
 mellitus--surgery--su; diabetes mellitus--therapy--th; dose response;
 drug delivery system; drug efficacy; Duchenne muscular dystrophy--drug
 therapy...

...therapy--th; enzyme replacement; Fabry disease--drug therapy--dt; gene
 expression; gene targeting; gene transfer; hematopoietic stem cell;
 hemophilia--drug therapy--dt; human; hydrodynamics; irradiation; ischemic
 heart disease; mucopolysaccharidosis type 7--drug...

...DRUG TERMS (UNCONTROLLED): combination--cb; cytosine phosphate diester
 guanine--pharmaceutics--pr; cytosine phosphate diester guanine
 --pharmacology--pd; Del 1 protein--drug combination--cb; Del 1 protein
 --drug therapy--dt; Del 1 protein--pharmaceutics--pr; Del 1 protein
 --pharmacology--pd; n (2,3 dioleyloxypropyl) n,n,n trimethylammonium
 chloride--drug combination--cb...

...CAS REGISTRY NO.: 9034-39-3 (growth hormone releasing factor);
 23491-52-3 (hoe 33342); 138415-13-1 (interleukin 12); 85898-30-2...

6/3,K/10 (Item 4 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0079621251 EMBASE No: 2003329267

What the paediatricians must know about rare diseases

Che cosa deve sapere il pediatra delle malattie rare

Ventura A.; Gagliardo A.; Berti I.; Marchetti F.

Affiliation unspecified.

Medico e Bambino (Med. Bambino) (Italy) May 31, 2003, 22/5 (292-307)

CODEN: MBAMF ISSN: 15913090

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: Italian SUMMARY LANGUAGE: English; Italian

NUMBER OF REFERENCES: 26

...in the diagnosis, treatment and care of children with rare diseases,
 focusing on six points: 1 . the need to be up-to-date on the diagnostic
 tools (for instance on the...

...in that of the nitrotrifluoromethylbenzoil-NTBC-in thyrocinemia), with
 hormones (as in the exemple of growth hormone in Turner syndrome), with
 surgery (as in the case of severe genetic craniostenosis), with enzymatic
 replacement (as in the case of Gaucher disease type I or Fabry disease),
 with bone marrow transplantation (as in the case of malignant
 osteopetrosis or in that of selected cases of...

DRUG DESCRIPTORS:

biotin--drug therapy--dt; bisphosphonic acid derivative--drug therapy--dt;
 enzyme inhibitor--drug therapy--dt; growth hormone --drug therapy--dt;
 penicillamine--drug therapy--dt; penicillin G--drug therapy--dt

MEDICAL DESCRIPTORS:

Albers Schoenberg disease--therapy--th; autoimmune disease ; biotinidase
 deficiency; bone marrow transplantation; craniofacial synostosis
 --surgery--su; diagnostic accuracy; diagnostic test; enzyme replacement;
 Fabry disease--drug therapy...

...CAS REGISTRY NO.: 9002-72-6 (growth hormone); 2219-30-9...

6/3,K/11 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

0079532027 EMBASE No: 2003238423

Regeneration therapy for diabetes mellitus

Yamaoka T.

Division of Genetic Information, Institute for Genome Research,
University of Tokushima, Tokushima, 770-8503, Japan

AUTHOR EMAIL: yamaoka@genome.tokushima-u.ac.jp

CORRESP. AUTHOR: Yamaoka T.

CORRESP. AUTHOR AFFIL: Division of Genetic Information, Institute for
Genome Research, University of Tokushima, Tokushima, 770-8503, Japan

CORRESP. AUTHOR EMAIL: yamaoka@genome.tokushima-u.ac.jp

Expert Opinion on Biological Therapy (Expert Opin. Biol. Ther.) (United
Kingdom) June 1, 2003, 3/3 (425-433)

CODEN: EOBTA ISSN: 14712598

DOI: 10.1517/eobt.3.3.425.21177

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 53

Regeneration therapy for diabetes mellitus

...lines, in conjunction with immunosuppressive therapy or
immunoisolation for the treatment of patients with Type 1 diabetes . In
the second type of regeneration therapy, ex vivo regeneration therapy, a
patient's own cells, such as bone marrow stem cells, are transiently
removed and induced to differentiate into beta-cells in vitro. However, at
the present time, insulin-producing cells cannot be generated from bone
marrow stem cells. In vivo regeneration therapy, the third type of
regeneration therapy, enables impaired tissue...

...in vivo have been considered in particular as regeneration therapies for
patients with Type 2 diabetes . Regeneration therapy for pancreatic
beta-cells can be combined with various other therapeutic strategies,
including...

...neogenesis; it is hoped that these strategies will, in the future,
provide a cure for diabetes .

DRUG DESCRIPTORS:

...drug therapy--dt; cytotoxic T lymphocyte antigen 4--drug therapy--dt;
daclizumab--drug therapy--dt; growth hormone ; hybrid protein--drug
therapy--dt; immunoglobulin--drug therapy--dt; insulin--drug administration
--ad; insulin--drug...

MEDICAL DESCRIPTORS:

*cell regeneration; *insulin dependent diabetes mellitus--drug therapy
--dt; *insulin dependent diabetes mellitus--therapy--th

...CAS REGISTRY NO.: 9002-72-6 (growth hormone); 9007-83-4 (
immunoglobulin); 9004-10-8 (insulin); 179045-86-4 (interleukin 2
receptor antibody...

6/3,K/12 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

0079190097 EMBASE No: 2002353867

Regeneration therapy of pancreatic beta cells: Towards a cure for diabetes?

Yamaoka T.

Division of Genetic Information, Institute for Genome Research,
University of Tokushima, Tokushima 770-8503, Japan

AUTHOR EMAIL: yamaoka@genome.tokushima-u.ac.jp

CORRESP. AUTHOR: Yamaoka T.

CORRESP. AUTHOR AFFIL: Division of Genetic Information, Institute for
Genome Research, University of Tokushima, Tokushima 770-8503, Japan

CORRESP. AUTHOR EMAIL: yamaoka@genome.tokushima-u.ac.jp

Biochemical and Biophysical Research Communications (Biochem. Biophys.
Res. Commun.) (United States) October 17, 2002, 296/5 (1039-1043)

CODEN: BBRCA ISSN: 0006291X

PUBLISHER ITEM IDENTIFIER: S0006291X02020004

DOI: 10.1016/S0006-291X(02)02000-4

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 13

Regeneration therapy of pancreatic beta cells: Towards a cure for diabetes ?

Regeneration therapy is an approach which could potentially move us towards a cure for type 1 diabetes . It is classified into three categories: (1) In vitro regeneration therapy using transplanted cultured cells, including ES cells, pancreatic stem cells, and...

...immunosuppressive therapy or immunoisolation. (2) In ex vivo regeneration therapy, patients' own cells, such as bone marrow stem cells, are transiently removed and induced to differentiate into beta cells in vitro. At present, however, insulin-producing cells cannot be generated from bone marrow stem cells. (3) In in vivo regeneration therapy, impaired tissues regenerate from patients' own cells...

...beta-cell proliferation in vivo have been considered, particularly as regeneration therapies for type 2 diabetes . Regeneration therapy of pancreatic beta cells can be combined with various other therapeutic strategies, including...

...and it is hoped that these strategies will, in the future, provide a cure for diabetes . (c) 2002 Elsevier Science (USA). All rights reserved.

DRUG DESCRIPTORS:

...therapy--dt; granulocyte colony stimulating factor--drug therapy--dt;
granulocyte colony stimulating factor--pharmacology--pd; growth hormone
--endogenous compound--ec; homeodomain protein--drug therapy--dt;
homeodomain protein--pharmacology--pd; insulin; insulin receptor...

MEDICAL DESCRIPTORS:

*insulin dependent diabetes mellitus--therapy--th; *non insulin dependent
diabetes mellitus--therapy--th; *pancreas islet beta cell
...gene transfer; graft rejection--drug therapy--dt; graft rejection
--prevention--pc; granulocytopenia--drug therapy--dt; hematopoietic stem
cell; human; hyperglycemia--drug resistance--dr; hypertension--side effect
--si; immune deficiency--side effect--si...

DRUG TERMS (UNCONTROLLED): homeobox protein 1 --drug therapy--dt; homeobox
protein 1 --pharmacology--pd

...CAS REGISTRY NO.: 9002-72-6 (growth hormone); 223747-03-3 (insulin
receptor substrate 2); 9004-10-8 (insulin); 179045-86-4 (interleukin...

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0079022055 EMBASE No: 2002185752

beta thalassemia major in Argentina

Torres A.F.; Bonduel M.; Sciuccati G.; Del Pozo A.; Roldan A.; Ciaccio M.
; Orazi V.; Fano V.; Ozuna B.; Lejarraga H.; Muriel F.S.

Serv. de Hematologia-Oncol., Hosp. Pedia. Prof. Dr. J.P. Garrahan,
Combate de los Pozos 1881, 1245 Buenos Aires, Argentina

CORRESP. AUTHOR: Torres A.F.

CORRESP. AUTHOR AFFIL: Serv. de Hematologia-Oncol., Hosp. Pedia. Prof.

Dr. J.P. Garrahan, Combate de los Pozos 1881, 1245 Buenos Aires,
Argentina

CORRESP. AUTHOR EMAIL: afeliutorres@yahoo.com

Medicina (Medicina (Argentina)) (Argentina) June 6, 2002, 62/2
(124-134)

CODEN: MEDCA ISSN: 00257680

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 43

...7%); IVS-I nt 110 (20%); IVS-I nt 6 (13.3%); IVS-I nt 1 (4%). alpha
globin genes were normal in 42 patients, 1 patient had triplicate and
cuadriplicate alpha globin genes and 2 patients were not analyzed. Six...

...5% of the patients. Impaired glucose tolerance was found in 2 patients.
No patient developed diabetes mellitus, thyroid or adrenal insufficiency.
One patient had cardiac complications. Forty-two patients are alive and 3
died (cardiac failure 1, central nervous system bleeding 1, sepsis 1
) . We conclude that beta thalassemia major, originated mainly from Italian
immigrants, has a cumbersome treatment...

DRUG DESCRIPTORS:

alloantibody--endogenous compound--ec; alpha globin--endogenous compound
--ec; beta globin--endogenous compound--ec; deferoxamine; growth hormone
--endogenous compound--ec; somatomedin C--endogenous compound--ec

MEDICAL DESCRIPTORS:

...body height; cause of death; central nervous system disease
--complication--co; clinical article; controlled study; diabetes mellitus
--complication--co; economic aspect; family; female; gene mutation; genetic
analysis; glucose intolerance--complication--co; growth rate; heart disease
--complication--co; heart failure--complication--co; hematopoietic stem
cell transplantation; heterozygote; hospital admission; human;
hypogonadotropic hypogonadism--complication--co; hypothyroidism
--complication--co; immigrant; infant...

...CAS REGISTRY NO.: 9002-72-6 (growth hormone); 67763-96-6 (
somatomedin C)

6/3,K/14 (Item 8 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0078479593 EMBASE No: 2001085531

**Granulocyte-macrophage colony stimulating factor (GM-CSF) antagonists:
Design and potential application**

Plugariu C.; Williams W.V.

SmithKline Beecham, Clinical Pharmacology, 51 North 39th Street,
Philadelphia, PA 19104, United States

CORRESP. AUTHOR: Williams W.V.

CORRESP. AUTHOR AFFIL: SmithKline Beecham, Clinical Pharmacology, 51
North 39th Street, Philadelphia, PA 19104, United States

Drugs of the Future (Drugs Future) (Spain) December 1, 2000, 25/12
(1295-1305)

CODEN: DRFUD ISSN: 03778282

DOI: 10.1358/dof.2000.025.12.858701

DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation

LANGUAGE: English

NUMBER OF REFERENCES: 91

DRUG DESCRIPTORS:

DNA vaccine; erythropoietin receptor; fibronectin; growth hormone
receptor; immunoglobulin E--endogenous compound--ec; immunoglobulin G
--endogenous compound--ec; interleukin 1 receptor; interleukin 3 receptor
; interleukin 4 receptor; interleukin 5 receptor; major histocompatibility
antigen; prolactin receptor...

MEDICAL DESCRIPTORS:

* autoimmune disease --drug therapy--dt; * autoimmune disease
--etiology--et; *inflammatory disease--drug therapy--dt; *inflammatory
disease--etiology--et
allergic disease--drug therapy--dt; aplastic anemia; asthma--drug therapy
--dt; bone marrow transplantation; cellular immunity; drug design; gene
expression; granulocyte; human; humoral immunity; leukopenia; lung alveolus
proteinosis...

6/3,K/15 (Item 9 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0076827294 EMBASE No: 1997120270

The somatogenic hormones and insulin-like growth factor-1: Stimulators of
lymphopoiesis and immune function

Clark R. // Clark R.

Endocrinology Group, Genentech, Inc., South San Francisco, CA 94080,
United States // Endocrinology Group, MS 37, Genentech Inc., 390 Pt San
Bruno Boulevard, South San Francisco, CA 94080, United States

CORRESP. AUTHOR: Clark R.

CORRESP. AUTHOR AFFIL: Endocrinology Group, Genentech, Inc., 390 Pt San
Bruno Boulevard, South San Francisco, CA 94080, United States

Endocrine Reviews (ENDOCR. REV.) (United States) May 6, 1997, 18/2
(157-179)

CODEN: ERVID ISSN: 0163769X

DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation

LANGUAGE: English

NUMBER OF REFERENCES: 287

The somatogenic hormones and insulin-like growth factor- 1 : Stimulators
of lymphopoiesis and immune function

DRUG DESCRIPTORS:

bromocriptine; growth hormone --endogenous compound--ec; growth
hormone receptor--endogenous compound--ec; prolactin--endogenous compound
--ec; prolactin receptor--endogenous compound--ec; somatomedin binding...

MEDICAL DESCRIPTORS:

apoptosis; bone marrow ; gastrointestinal tract; growth hormone
release; hormonal regulation; human; insulin dependent diabetes mellitus;
lymphocyte proliferation; nonhuman; polycythemia vera--etiology--et;
pregnancy; priority journal; prolactin release; review; signal...

...CAS REGISTRY NO.: 9002-72-6 (growth hormone); 12585-34-1...

6/3,K/16 (Item 10 from file: 73)
 DIALOG(R)File 73:EMBASE
 (c) 2007 Elsevier B.V. All rts. reserv.

0076514735 EMBASE No: 1996191584

The immune effects of neuropeptides

Berczi I.; Chalmers I.M.; Nagy E.; Warrington R.J.
 Department of Immunology, University of Manitoba, 795 McDermot Avenue,
 Winnipeg, Man. R3E 0W3, Canada
 CORRESP. AUTHOR: Berczi I.
 CORRESP. AUTHOR AFFIL: Department of Immunology, University of Manitoba,
 795 McDermot Avenue, Winnipeg, Man. R3E 0W3, Canada

Bailliere's Clinical Rheumatology (BAILLIERE'S CLIN. RHEUMATOL.) (United Kingdom) July 2, 1996, 10/2 (227-257)
 CODEN: BCRHE ISSN: 09503579
 DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
 LANGUAGE: English SUMMARY LANGUAGE: English

...indicates that the neuroendocrine system is the highest regulator of immune/inflammatory reactions. Prolactin and growth hormone stimulate the production of leukocytes, including lymphocytes, and maintain immunocompetence. The hypothalamus-pituitary-adrenal axis...

...cytokine mediators which reach significant blood levels (cytokine-hormones) during systemic immune/inflammatory reactions. Interleukin- 1 , -6, and TNF-alpha are the major cytokine hormones mediating the acute phase response. These...

...relies heavily on the neuroimmunoregulatory network. Moreover, abnormalities of neuroimmunoregulation contribute to the aetiology of autoimmune disease , chronic inflammatory disease, immunodeficiency, allergy, and asthma. Finally, neuroimmune mechanisms play an important role in...

MEDICAL DESCRIPTORS:

antibody response; bone marrow ; cellular immunity; embryo development; human; hypothalamus hypophysis adrenal system; inflammation--etiology--et; nomenclature; phagocytosis; priority...

?

Set	Items	Description
S1	11985	(THYMUS OR THYMIC) (S) (STIMULATION OR REGENERATION OR ACTIVATING OR REACTIVATING)
S2	302921	1 AND ((AUTOIMMUNE (W) DISEASE) OR DIABETES)
S3	0	S2 AND (LUPROLIDE)
S4	4572	S2 AND (IL-7 OR (GROWTH (W) HORMONE))
S5	18	S4 AND ((BONE (W) MARROW) OR HSC OR (HEMATOPOIETIC (W) STEM))
S6	16	RD (unique items)

?

S (TRANSPLANTATION OR IMPLANTATION) (S) ((BONE (W) MARROW) OR (HEMATOPOIETIC (W) STEM))
 1760083 TRANSPLANTATION
 253353 IMPLANTATION
 1518872 BONE
 587876 MARROW

```

556291 BONE(W)Marrow
206560 HEMATOPOIETIC
551584 STEM
110649 HEMATOPOIETIC(W)STEM
11442 HSC
S7 178944 (TRANSPLANTATION OR IMPLANTATION) (S) ((BONE (W) Marrow)
OR (HEMATOPOIETIC (W) STEM) OR HSC)

```

?

```

S S7 (S) (AUTOIMMUNITY OR (AUTOIMMUNE (W) DISEASE) OR DIABETES)
178944 S7
76680 AUTOIMMUNITY
235396 AUTOIMMUNE
8252380 DISEASE
67459 AUTOIMMUNE(W)DISEASE
743813 DIABETES
S8 1525 S7 (S) (AUTOIMMUNITY OR (AUTOIMMUNE (W) DISEASE) OR
DIABETES)

```

?

```

S (T (W) CELL) (S) (DEPLETION OR DEPLETING OR ABLATING OR ABLATION)
Processing
2567657 T
9883878 CELL
241885 DEPLETION
14451 DEPLETING
2446 ABLATING
99381 ABLATION
S9 20736 (T (W) CELL) (S) (DEPLETION OR DEPLETING OR ABLATING OR
ABLATION)

```

?

```

S S8 AND S9
1525 S8
20736 S9
S10 75 S8 AND S9

```

?

```

RD
S11 35 RD (unique items)

```

?

```

S S11 NOT PY>1999
35 S11
13545857 PY>1999
S12 14 S11 NOT PY>1999

```

?

T S12/3,K/ALL

12/3,K/1 (Item 1 from file: 155)
 DIALOG(R) File 155:MEDLINE(R)
 (c) format only 2007 Dialog. All rts. reserv.

12554550 PMID: 10501430

Autologous stem cell transplantation: a possible treatment for refractory juvenile chronic arthritis?

Wulffraat N M; Kuis W

Department of Paediatric Immunology, University Hospital for Children, 'Het Wilhelmina Kinderziekenhuis', Utrecht, The Netherlands.

Rheumatology (Oxford, England) (ENGLAND) Aug 1999, 38 (8) p764-6,
ISSN 1462-0324--Print Journal Code: 100883501
Publishing Model Print
Document type: Clinical Trial; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... METHODS: We studied three children with systemic JCA and one child with polyarticular JCA. Unprimed bone marrow was harvested 1 month prior to ASCT. T-cell depletion of the graft was performed with CD2 and CD3 antibodies. We used a preparative regimen...

... reactive protein (CRP) and haemoglobin (Hb) returned to near-normal values within 6 weeks. Despite T - cell depletion, there was a very rapid immune reconstitution. Two patients developed a limited varicella zoster virus...

12/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

12340936 PMID: 10091416
Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.
Watanabe T; Kawano Y; Watanabe A; Takaue Y
Department of Pediatrics, University of Tokushima, Japan.
twatanab@clin.med.tokushima-u.ac.jp
Haematologica (ITALY) Feb 1999, 84 (2) p167-76, ISSN 0390-6078--
Print Journal Code: 0417435
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

...fraction can range from 30% to 90%, and two to three logs of T-cell depletion can be achieved. Tumor cell contamination has not yet been fully evaluated. The clonogenic activity...

... a source of dendritic cells for cancer immunotherapy and for the treatment of patients with autoimmune disease .

12/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

12310141 PMID: 10028984
Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis.
Wulffraat N; van Royen A; Bierings M; Vossen J; Kuis W
Department of Pediatric Immunology and Haematology, University Hospital for Children Het Wilhelmina kindziekenhuis, Utrecht, The Netherlands.
N.Wulffraat@WKZ.AZU.NL
Lancet (ENGLAND) Feb 13 1999, 353 (9152) p550-3, ISSN 0140-6736--
Print Journal Code: 2985213R
Publishing Model Print; Comment in Lancet. 1999 May 29;353(9167) 1885;
Comment in PMID 10359442; Comment in Lancet. 1999 May 29;353(9167):1885-6;

Comment in PMID 10359443; Erratum in Lancet 1999 Aug 28;354(9180):780

Document type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... METHODS: We studied three children with systemic JCA and one child with polyarticular JCA. Unprimed bone marrow was taken 1 month before AHSCT. T-cell depletion of the graft was done with CD2 and CD3 antibodies. We used a preparative regimen...

... rate, C-reactive protein, and haemoglobin returned to almost normal values within 6 weeks. Despite T - cell depletion there was a rapid immune reconstitution in three out of four children. Two patients developed ...

12/3,K/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

11980901 PMID: 9808541

Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.

Burt R K; Traynor A E; Pope R; Schroeder J; Cohen B; Karlin K H; Lobeck L ; Goolsby C; Rowlings P; Davis F A; Stefoski D; Terry C; Keever-Taylor C; Rosen S; Vesole D; Fishman M; Brush M; Mujias S; Villa M; Burns W H

Departments of Medicine, Neurology, Nephrology, and Rheumatology, Division of Hematology/Oncology & Lurie Comprehensive Cancer Center, Northwestern University Medical School and Robert H. Lurie Cancer Center, Chicago, IL, USA.

Blood (UNITED STATES) Nov 15 1998, 92 (10) p3505-14, ISSN 0006-4971

--Print Journal Code: 7603509

Publishing Model Print

Document type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation .

... 5 to 17 months (median, 11 months). We conclude that intense immunosuppressive conditioning and autologous T - cell -depleted hematopoietic transplantation was safely used to treat these 10 patients with severe autoimmune disease . Although durability of response is as yet unknown, all patients have demonstrated stabilization or improvement.

12/3,K/5 (Item 5 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

11965332 PMID: 9793258

Stem cell transplantation for severe autoimmune diseases: progress and problems.

Marmont A M

II Division of Hematology, S. Martino's Hospital, Genoa, Italy.

Haematologica (ITALY) Aug 1998, 83 (8) p733-43, ISSN 0390-6078--

Print Journal Code: 0417435
Publishing Model Print
Document type: Journal Article; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... clinical AID in SCID mice. Allogeneic stem cell transplantation demonstrated therapeutic potential in fully developed autoimmune disease . Mixed allogeneic chimerism induced by a sublethal approach has also been shown to prevent and...

...be cured by means of total body irradiation (TBI) followed by autologous hemolymphopoietic stem cell (HSC) transplantation . It was postulated that the newly developing T cells might be tolerant to self antigens. The transfer of AID from affected donors to recipients of allogeneic HSC transplants has been reported for many organ-specific AID, including diabetes (IDDM), thyroiditis, myasthenia gravis and thrombocytopenic purpura (AITP); rheumatoid arthritis (RA) and systemic lupus erythematosus ...

... far as concerns a resolution of AID, because they may also exert a graft-versus- autoimmunity effect by gradually eradicating the recipient's lymphopoiesis, but transplant related mortality (TRM) is considered...

... worst in refractory autoimmune thrombocytopenic purpura. No definite conclusions as to the efficacy of autologous HSC transplantation , from marrow or from blood, with or without T-cell depletion , may be drawn at this time, but the feeling is that real cures will be...

12/3,K/6 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

11778763 PMID: 9597144
How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
Waldmann H; Cobbold S
Sir William Dunn School of Pathology, Oxford, United Kingdom.
Annual review of immunology (UNITED STATES) 1998, 16 p619-44, ISSN 0732-0582--Print Journal Code: 8309206
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... in its induction and its maintenance. In a number of allogeneic transplant models (heart, skin, bone marrow) anti-CD4 (+/- CD8) antibodies can be shown to block the rejection process while selectively promoting...

... antibodies, then tolerance can be achieved through clonal deletion. The mechanism by which regulatory CD4+ T cell suppress is not yet defined but could be active or passive. We have proposed the...

12/3,K/7 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

11526402 PMID: 9358994

Hemopoietic blood and marrow transplants in the treatment of severe autoimmune disease.

Tyndall A; Gratwohl A

Department of Rheumatology, Felix Platter Spital, Basel, Switzerland.

Current opinion in hematology (UNITED STATES) Nov 1997, 4 (6) p390-4

, ISSN 1065-6251--Print Journal Code: 9430802

Publishing Model Print

Document type: Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... sclerosis or scleroderma) have clinically improved or stabilized; the toxicity of the procedure (mostly autologous bone marrow transplantation) was as observed previously in other disorders; and better results are suggested in patients achieving significant T-cell depletion, either through conditioning, graft purging, or both. These impressions must be confirmed by prospective comparative...

12/3,K/8 (Item 8 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

11335205 PMID: 9150112

Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases.

Marmont A M

Division of Hematology, S. Martino's Hospital, Genoa, Italy.

Journal of rheumatology. Supplement (CANADA) May 1997, 48 p13-8,

ISSN 0380-0903--Print Journal Code: 7806058

Publishing Model Print

Document type: Case Reports; Journal Article; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... autoimmune disease have been successfully used to explore peripheral stem cell transfusion and bone marrow transplantation. Allogeneic marrow transplants have been shown to suppress lupus-like disease and experimental allergic encephalomyelitis. Autologous transplantation has also been successful in adjuvant arthritis. Operationally, these may be considered as graft versus autoimmunity effects. In humans, adoptive autoimmunity, in which the donor becomes apparent in the recipient, has been documented for myasthenia gravis and insulin dependent diabetes mellitus. Of 9 allogeneic bone marrow transplants for rheumatoid arthritis, 4 patients have done well for many years while one relapsed after 2 years. In 2 cases, autologous marrow transplant has been used specifically to treat autoimmune disease: one patient with CREST had only a transient response and one patient with myasthenia gravis had remission. While allogeneic bone marrow transplant is the most rational procedure, its use in nonmalignant disorders must be very carefully...

... its toxicity and potential morbidity. The use of peripheral blood CD34+ cells with T cell depletion, may promise complete or partial longterm remission but results of this therapy need to be...

12/3,K/9 (Item 9 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

10808273 PMID: 9700362
Differential effects of X-irradiation and cyclosporin-A administration on the thymus with respect to the generation of cyclosporin-A-induced autoimmunity.
Beijleveld L J; Damoiseaux J G; Van Breda Vriesman P J
Department of Immunology, Faculty of Medicine, University of Limburg, Maastricht, The Netherlands.
Developmental immunology (ENGLAND) 1995, 4 (2) p127-38, ISSN 1044-6672--Print Journal Code: 9200624
Publishing Model Print
Document type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... marrow transplantation, and a 4-week course of CsA administration causes the development of an autoimmune disease (CsA-AI) resembling allogeneic graft-versus-host disease. This occurs upon withdrawal of CsA, provided...
... density on these cells were not observed. Irradiation on the other hand causes a strong depletion of thymocytes. The thymocyte population is recovered within 2 weeks and a cortical and medullary...

12/3,K/10 (Item 10 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

10537475 PMID: 7631156
Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation.
Blank M; Tomer Y; Slavin S; Shoenfeld Y
Department of Medicine B, Tel-Aviv University, Israel.
Scandinavian journal of immunology (ENGLAND) Aug 1995, 42 (2) p226-34, ISSN 0300-9475--Print Journal Code: 0323767
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... the clinical findings characteristic to the respective autoimmune disease. The effects of syngeneic bone marrow transplantation (BMT) on experimental anti-phospholipid syndrome (APS) were investigated. BALB/c mice were immunized with...

... a high percentage of fetal resorptions. These mice were then lethally irradiated and transfused with bone marrow (BM) cells (T cell depleted) from syngeneic naive mice. The titres of antiphospholipid antibodies were ...

... in the recipients. The decrease in titre of autoantibodies was found to be related to depletion of antibody forming cells in vivo, associated with reduced proliferative response of lymph node cells...

... with a monoclonal anti-DNA antibody. We conclude that acute myeloablative immunosuppression combined with syngeneic bone marrow transplantation may induce a state of tolerance to the pathogenic autoantibodies in mice with experimental APLS...

12/3,K/11 (Item 11 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

10415933 PMID: 7697909

Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).

Karussis D M; Vourka-Karussis U; Lehmann D; Abramsky O; Ben-Nun A; Slavin S

Department of Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel.

Clinical and experimental immunology (ENGLAND) Apr 1995, 100 (1) p111-7, ISSN 0009-9104--Print Journal Code: 0057202

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).

... controls. CY was more effective than TBI in reducing the anti-DNA titres. Likewise, T depletion of bone marrow inocula before BMT induced a more drastic drop in autoantibodies, following both...

... examination, the BMT-treated mice displayed normal glomeruli with occasional minimal signs of glomerulonephritis. Syngeneic T cell-depleted BMT following acute cyto reduction of anti-self immune lymphocytes may represent a new therapeutic...

12/3,K/12 (Item 12 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

08546040 PMID: 2373992

Thymus and autoimmunity: capacity of the normal thymus to produce pathogenic self-reactive T cells and conditions required for their induction of autoimmune disease.

Sakaguchi S; Sakaguchi N

Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.

Journal of experimental medicine (UNITED STATES) Aug 1 1990, 172 (2) p537-45, ISSN 0022-1007--Print Journal Code: 2985109R

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... nu mice. Autoimmune disease developed, however, when adult thymuses were irradiated at a T cell-depleting dose before transplantation. Engrafting newborn thymuses into BALB/c mice T cell depleted by thymectomy, irradiation, and bone marrow transplantation produced

similar organ-specific autoimmune disease as well, but thymus engrafting into T cell -nondepleted BALB/c mice (i.e., mice thymectomized as adults, but not irradiated) did not...

... that transplanted thymuses grew well in both groups of mice. The mice with organ-specific autoimmune disease produced autoantibodies specific for the respective organ components, such as gastric parietal cells, thyroglobulins, oocytes...

... results indicate that: (a) the thymus of a murine strain that does not develop spontaneous autoimmune disease can produce pathogenic self-reactive T cells that mediate organ-specific and/or systemic autoimmune diseases; and (b) such self-reactive T cells, especially those mediating organ-specific autoimmune disease, spontaneously expand and cause autoimmune disease when released to the T cell -deficient or -eliminated periphery.

12/3,K/13 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

12768000 BIOSIS NO.: 199598235833

Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT)

AUTHOR: Karussis D M (Reprint); Vourka-Karussis U; Lehmann D; Abramsky O; Ben-Nun A; Slavin S

AUTHOR ADDRESS: Dep. Neurol., Hadassah Univ. Hosp., Jerusalem, IL-91120, Israel**Israel

JOURNAL: Clinical and Experimental Immunology 100 (1): p111-117 1995 1995

ISSN: 0009-9104

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT)

...ABSTRACT: controls. CY was more effective than TBI in reducing the anti-DNA titres. Likewise, T depletion of bone marrow inocula before BMT induced a more drastic drop in autoantibodies, following both...

...examination, the BMT-treated mice displayed normal glomeruli with occasional minimal signs of glomerulonephritis. Syngeneic T cell -depleted BMT following acute cytoreduction of anti-self immune lymphocytes may represent a new therapeutic...

12/3,K/14 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

0076064363 EMBASE No: 1995106314

Immune ablation followed by stem cell rescue: A new radical approach to the treatment of severe autoimmune diseases
Marmont A.M.

Divisione di Ematologia II, Centro il Trapianto di Midollo Osseo, Ospedale San Martino, Viale Benedetto XV.10, 16132 Genova, Italy

CORRESP. AUTHOR: Marmont A.M.

CORRESP. AUTHOR AFFIL: Divisione di Ematologia II, Centro il Trapianto di

Midollo Ossea, Ospedale San Martino, Viale Benedetto XV.10, 16132 Genova, Italy

FORUM - Trends in Experimental and Clinical Medicine (FORUM TRENDS EXP. CLIN. MED.) (Italy) April 11, 1995, 5/1 (24-35)

CODEN: FTCME ISSN: 11218142

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

...immunointerventions, but remissions have been up to now brief. A different strategy is based on ablation (or extreme immunosuppression) of the faulty immune system, followed by substitution and/or rescue with...
...founded on two pieces of evidence: stem cell transfers in animals and, more recently, adoptive autoimmunity following allogeneic BM transplantation and, conversely, resolution of pre-existing autoimmunity after transplantation. The advantages and disadvantages of utilising allogeneic and/or autologous stem cells are discussed.

?

Set	Items	Description
S1	11985	(THYMUS OR THYMIC) (S) (STIMULATION OR REGENERATION OR ACTIVATING OR REACTIVATING)
S2	302921	1 AND ((AUTOIMMUNE (W) DISEASE) OR DIABETES)
S3	0	S2 AND (LUPROLIDE)
S4	4572	S2 AND (IL-7 OR (GROWTH (W) HORMONE))
S5	18	S4 AND ((BONE (W) MARROW) OR HSC OR (HEMATOPOIETIC (W) STEM))
S6	16	RD (unique items)
S7	178944	(TRANSPLANTATION OR IMPLANTATION) (S) ((BONE (W) MARROW) OR (HEMATOPOIETIC (W) STEM) OR HSC)
S8	1525	S7 (S) (AUTOIMMUNITY OR (AUTOIMMUNE (W) DISEASE) OR DIABETES)
S9	20736	(T (W) CELL) (S) (DEPLETION OR DEPLETING OR ABLATING OR AB-LATION)
S10	75	S8 AND S9
S11	35	RD (unique items)
S12	14	S11 NOT PY>1999

?

S S10 AND (LEUPROLIDE)

	75	S10
	5780	LEUPROLIDE
S13	0	S10 AND (LEUPROLIDE)

?

Set	Items	Description
S1	11985	(THYMUS OR THYMIC) (S) (STIMULATION OR REGENERATION OR ACTIVATING OR REACTIVATING)
S2	302921	1 AND ((AUTOIMMUNE (W) DISEASE) OR DIABETES)
S3	0	S2 AND (LUPROLIDE)
S4	4572	S2 AND (IL-7 OR (GROWTH (W) HORMONE))
S5	18	S4 AND ((BONE (W) MARROW) OR HSC OR (HEMATOPOIETIC (W) STEM))
S6	16	RD (unique items)
S7	178944	(TRANSPLANTATION OR IMPLANTATION) (S) ((BONE (W) MARROW) OR (HEMATOPOIETIC (W) STEM) OR HSC)
S8	1525	S7 (S) (AUTOIMMUNITY OR (AUTOIMMUNE (W) DISEASE) OR DIABETES)

`S9 20736 (T (W) CELL) (S) (DEPLETION OR DEPLETING OR ABLATING OR AB-
 LATION)
S10 75 S8 AND S9
S11 35 RD (unique items)
S12 14 S11 NOT PY>1999
S13 0 S10 AND (LEUPROLIDE)
?

S S10 AND (CHEMICAL (W) CASTRATION)
 75 S10
 4631556 CHEMICAL
 52597 CASTRATION
 469 CHEMICAL(W) CASTRATION
S14 0 S10 AND (CHEMICAL (W) CASTRATION)
?

Set	Items	Description
S1	11985	(THYMUS OR THYMIC) (S) ((STIMULATION OR REGENERATION OR ACT- IVATING OR REACTIVATIING)
S2	302921	1 AND ((AUTOIMMUNE (W) DISEASE) OR DIABETES)
S3	0	S2 AND (LUPROLIDE)
S4	4572	S2 AND (IL-7 OR (GROWTH (W) HORMONE))
S5	18	S4 AND ((BONE (W) MARROW) OR HSC OR (HEMATOPOIETIC (W) STE- M))
S6	16	RD (unique items)
S7	178944	(TRANSPLANTATION OR IMPLANTATION) (S) ((BONE (W) MARROW) OR (HEMATOPOIETIC (W) STEM) OR HSC)
S8	1525	S7 (S) (AUTOIMMUNITY OR (AUTOIMMUNE (W) DISEASE) OR DIABET- ES)
S9	20736	(T (W) CELL) (S) (DEPLETION OR DEPLETING OR ABLATING OR AB- LATION)
S10	75	S8 AND S9
S11	35	RD (unique items)
S12	14	S11 NOT PY>1999
S13	0	S10 AND (LEUPROLIDE)
S14	0	S10 AND (CHEMICAL (W) CASTRATION)
		?

COST

26dec07 14:20:26 User259876 Session D1058.2
 \$8.27 2.432 DialUnits File155
 \$3.30 15 Type(s) in Format 3
 \$3.30 15 Types
 \$11.57 Estimated cost File155
 \$1.96 0.623 DialUnits File159
 \$1.96 Estimated cost File159
 \$22.07 3.678 DialUnits File5
 \$9.20 4 Type(s) in Format 3
 \$9.20 4 Types
 \$31.27 Estimated cost File5
 \$32.77 2.754 DialUnits File73
 \$36.30 11 Type(s) in Format 3
 \$36.30 11 Types
 \$69.07 Estimated cost File73
 OneSearch, 4 files, 9.487 DialUnits FileOS
 \$3.73 INTERNET
 \$117.60 Estimated cost this search
 \$118.63 Estimated total session cost 9.766 DialUnits
 ?

Return to logon page!